Answers are grounded in this paper and cite their sources.
Therefore, although biomarkers are not ready for prime time as diagnostic tests in IBS, some biomarkers could identify subgroups of patients with IBS for inclusion in clinical trials that target specific dysfunctions. Such an approach may enhance treatment efficacy, and may ultimately help reduce costs in drug development and in the management of patients in clinical practice.
No takes yet. Share an insight, caveat, or question.
Michael Camilleri (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: